CARRERA CARRERA, FRANCESC,GARCIA GONZALEZ, NURIA,SERRA MASIA, XAVIER,JULIA JANE, MONTSERRAT,DEBETHUNE, LAURENT
申请号：
NZ59449110
公开号：
NZ594491A
申请日:
2010.03.11
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
594491 Disclosed herein is a crystalline addition salt of tromethamine with an azabiphenylaminobenzoic acid derivative of formula (I), wherein the variables are defined in the specification； a pharmaceutical composition comprising said salt and one or more other therapeutic agents selected from anti-TNF-alpha monoclonal antibodies, TNF-alpha antagonists, calcineurin (PP-2B) inhibitors/INS expression Inhibitors, IL-1 receptor antagonists, Anti-CD20 monoclonal antibodies, p38 Inhibitors, NF-kappaB (NFKB) activation Inhibitors, dihydrofolate reductase (DHFR) Inhibitors, JAK3 Inhibitors, MEK inhibitors, S1 P1 agonists, interferons, inmunomodulators, and UD adenosine aminohydrolase inhibitors； and the use of said pharmaceutical composition in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of dihydroorotate dehydrogenage such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondilytis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis and sarcoidosis.
